Log in to search using one of your social media accounts:

 

Istalol (Timolol Maleate Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 20, 2017 Category: Drugs & Pharmacology Source Type: news

Timoptic in Ocudose (Timolol Maleate Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 28, 2016 Category: Drugs & Pharmacology Source Type: news

timolol (Blocadren and Timolide 10-25 have been discontinued)
Title: timolol (Blocadren and Timolide 10-25 have been discontinued)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 9/23/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 23, 2016 Category: Cardiology Source Type: news

Timoptic (Timolol Maleate Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 1, 2016 Category: Drugs & Pharmacology Source Type: news

Topical timolol improves thinnest infantile hemangiomas
Topical timolol maleate acts as an effective alternate to oral propranolol for treatment of certain infantile hemangiomas (IHs), based on data from a retrospective study of 731 children. The findings were published online August 15 in Pediatrics. “Superficial, relatively thin IHs, regardless of... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 15, 2016 Category: Dermatology Source Type: news

Allergan picks up ForSight Vision for $95m
Allergan (NYSE: AGN) said today it inked a deal to buy drug-eluting ophthalmological implant maker ForSight Vision5 for $95 million up front, with a possible milestone payment for launching its drug-eluting device. Pharmaceutical giant Allergan said the device, known as the Helios ring, is designed for extended drug delivery and for reducing intraocular pressure in glaucoma patients. The Helios is designed to rest on the surface of the eye under the eyelids to release bimatoprost over multiple months to lower IOP in glaucoma and ocular hypertensive patients, Allergan said. “The acquisition of ForSight and its oc...
Source: Mass Device - August 11, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Optical/Ophthalmic Allergan Inc. ForSight Vision Source Type: news

ForSight Vision5’s Helios implant delivers at 6 months in Phase II trial
The Helios drug-eluting implant developed by ForSight Vision5 lowered intraocular pressure in glaucoma patients by about 20% after 6 months, according to study results published today in Ophthalmology, the journal of the American Academy of Ophthalmology. The Helios device is a thin, silicone ring impregnated with the glaucoma drug bimatoprost that’s designed to slowly release the drug for 6 months. The aim is to overcome the compliance issue that dogs patient-administered eye drops. The 130-patient Phase II trial compared 64 patients implanted with the Helios ring with a control arm of 66 patients implante...
Source: Mass Device - May 5, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Optical/Ophthalmic ForSight Vision Glaucoma Source Type: news

Glaucoma Drops May Help in Refractory AMDGlaucoma Drops May Help in Refractory AMD
When age-related macular degeneration (AMD) is refractory to intravitreous anti-vascular endothelial growth factor (anti-VEGF), adding dorzolamide-timolol eye drops may be helpful, according to a small pilot study. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 5, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Betimol (Timolol Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 22, 2016 Category: Drugs & Pharmacology Source Type: news

Sylentis announces top-line results from Phase II study for RNAi drug in Glaucoma
(Pharmamar) The SYLTAG study, which includes 184 patients with a baseline IOP greater than or equal to 23 mm Hg, evaluates the efficacy and safety of four doses 0.375 percent (150 micrograms); 0.75 percent (300 micrograms); 1.125 percent (450 micrograms) y 1.5 percent (600 micrograms) given once a day for 28 days. The comparator group received timolol (0.5 percent), given twice a day. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 2, 2015 Category: Global & Universal Source Type: news

Topical timolol reduces facial angiofibromas in tuberous sclerosis
Topical beta-blockers could be an alternative to rapamycin for the treatment of angiofibromas after traditional destructive procedures such as ablative laser resurfacing, according to a case study published in the Aug. 24 edition of Pediatrics. A 26-year-old woman with tuberous sclerosis complex... (Source: Skin and Allergy News)
Source: Skin and Allergy News - August 24, 2015 Category: Dermatology Source Type: news

Open-angle glaucoma: Poor data for the fixed combination tafluprost/timolol
Research that focused on open-angle glaucoma provided study results that are uncertain, claiming that information on important outcomes is lacking. As such, no added benefit can be determined for the fixed combination of tafluprost and timolol. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2015 Category: Science Source Type: news

Latanoprostene Beats Timolol for Ocular Perfusion PressureLatanoprostene Beats Timolol for Ocular Perfusion Pressure
The experimental drug latanoprostene bunod improves ocular perfusion pressure more than timolol, during both day and night, a new study shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

RTP drug developer speeds up glaucoma trial
Duke University spinout Aerie Pharmaceuticals, will accelerate reporting results of a trial testing its experimental glaucoma treatment. Aerie (Nasdaq: AERI) says it is ahead of schedule in a 400-patient Phase 3 registration trial of Rhopressa, Aerie's developmental eye drop is being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Specifically, Aerie's drug is being tested against the prescription drug timolol, sold under brand names including… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - January 12, 2015 Category: Hospital Management Authors: Jason deBruyn Source Type: news

timolol ophthalmic solution (Timoptic, Timoptic-XE, Timoptic in Ocudose)
Title: timolol ophthalmic solution (Timoptic, Timoptic-XE, Timoptic in Ocudose)Category: MedicationsCreated: 5/11/1998 12:00:00 AMLast Editorial Review: 12/10/2014 12:00:00 AM (Source: MedicineNet Eyesight General)
Source: MedicineNet Eyesight General - December 10, 2014 Category: Opthalmology Source Type: news

Nanodiamond Contact Lenses Could Enable More Efficient Glaucoma Drug Delivery
Researchers at the UCLA School of Dentistry have developed a nanodiamond-embedded contact lens that may provide an effective way of delivering glaucoma medicine to patients’ eyes. Nanodiamonds carrying timolol, a compound commonly used to treat glaucoma, are attached to the contact lenses, and the timolol is then released when the nanodiamonds come into contact with lysozyme, a common enzyme in human tears (Source: Medical Design Online News)
Source: Medical Design Online News - February 27, 2014 Category: Medical Equipment Source Type: news

Chronic Wounds May Respond to Topical TimololChronic Wounds May Respond to Topical Timolol
Chronic wounds that do not heal may respond to topical timolol, a topical beta-adrenergic receptor antagonist used to treat glaucoma, a new case series suggests. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 8, 2013 Category: Consumer Health News Tags: Dermatology News Source Type: news

Istalol (Timolol Maleate Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 1, 2013 Category: Drugs & Pharmacology Source Type: news

Infantile Hemangiomas: Daily Timolol Maleate Slows GrowthInfantile Hemangiomas: Daily Timolol Maleate Slows Growth
The gel formulation of a medicine approved in 1978 to treat glaucoma slows the growth of potentially disfiguring infantile hemangiomas with few of the adverse effects that limit other treatments. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 6, 2013 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Timolol to Treat Myopic Regression After LASIKTimolol to Treat Myopic Regression After LASIK
If it works, timolol therapy might result in happier patients after LASIK. Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - January 14, 2013 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news